Successful human ovarian autotransplantation to the upper arm

Oktay, Kutluk

doi:10.1002/cncr.21001

Cited by 8 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Options for female patients include embryo and oocyte cryopreservation, ovarian tissue cryopreservation and ovarian suppression with gonadotropin-releasing hormone (GnRH) agonists. [17,[25][26][27][28][29] Recent improvements in ovarian stimulation, oocyte and embryo freezing and ovarian tissue grafting have improved outcomes with the use of ART following FP.…”

Section: Introductionmentioning

confidence: 99%

A Study Protocol for the Australasian Oncofertility Registry: Monitoring Referral Patterns and the Uptake, Quality, and Complications of Fertility Preservation Strategies in Australia and New Zealand

Anazodo

Stern

McLachlan

et al. 2016

Journal of Adolescent and Young Adult Oncology

View full text Add to dashboard Cite

Improvements in cancer diagnosis and treatment in patients of a reproductive age have led to significant improvements in survival rates; however, a patient's fertility can be affected by both cancer and its treatment. As survival rates improve, there is an expectation by clinicians and patients that patient's reproductive potential should be considered and protected as much as possible. However, there is a lack of data about current fertility preservation (FP) uptake as well as accurate data on the acute or permanent reproductive risks of cancer treatment, complications of FP in cancer patients, and the use and success of assisted reproductive technology by cancer survivors. FP remains a major gap in acute cancer management with lifelong implications for cancer survivors. The FUTuRE Fertility research team has established the first binational multisite Australasian Oncofertility Registry, which is collecting a complete oncofertility data set from cancer and fertility centers in Australia and New Zealand. Outcomes from the research study will monitor referral, uptake, and complications of FP, document patient's reproductive potential after treatment, and collect data on the use of assisted reproductive technology following cancer treatment. The data will be linked to other routine health and administrative data sets to allow for other research projects to be carried out. The changes in oncofertility care will be benchmarked against the Australasian Oncofertility Charter. The data will be used to develop evidence-based guidelines and resources, including development of accurate risk projections for patients' risk of infertility, allowing clinicians to make recommendations for FP or assisted reproductive technology. Australian New Zealand Clinical Trials Number-12615000221550.

show abstract

Section: Introductionmentioning

confidence: 99%

A Study Protocol for the Australasian Oncofertility Registry: Monitoring Referral Patterns and the Uptake, Quality, and Complications of Fertility Preservation Strategies in Australia and New Zealand

Anazodo

Stern

McLachlan

et al. 2016

Journal of Adolescent and Young Adult Oncology

View full text Add to dashboard Cite

show abstract

“…Anatomic locations utilized in transplanting cryopreserved ovarian tissue have varied. Heterotopic sites such as the subcutaneous of the abdominal wall, or forearm and rectus muscle generally have functioned well as reservoirs for ovarian restoration [ 4 5 6 ]. For the present study, we chose the abdominal wall, given the temperature and blood flow benefits of a subcutaneous environment and the relative ease of surgical access [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Expression of angiogenic factors in cryopreserved mouse ovaries after heterotopic autotransplantation

et al. 2015

View full text Add to dashboard Cite

ObjectiveRevascularization is critical for successful ovarian tissue transplantation. Vascular endothelial growth factor (VEGF) and angiopoietin-2 (angpt-2) are the principal mediators of neovascularization. This study was designed to assess VEGF and angpt-2 levels in cryopreserved ovarian tissue after heterotopic autotransplantation.MethodsOvarian tissues harvested from ICR mice at 5 to 6 weeks of age were stratified as follows: no cryopreservation (controls, group I); vitrification in VFS-40 (vitrification, group II); and gradual freezing in dimethyl sulfoxide (slow-freezing, group III). Frozen specimens were thawed at room temperature, assaying VEGF and angpt-2 levels 1 week after cryopreservation and 2 weeks after autotransplantation.ResultsVEGF and angpt-2 protein levels were significantly lower in cryopreserved ovaries of groups II and III than in controls (group I, P<0.05), whereas groups II and III did not differ significantly in this regard. After autotransplantation of cryopreserved ovarian tissue, VEGF and angpt-2 protein levels did not differ significantly by technique but tended to be lower than corresponding levels in controls.ConclusionExpression of angiogenic factors in ovarian tissue is thought to vary by method of cryopreservation. Our findings indicate that levels of angiogenic factors expressed in cryopreserved ovarian tissue after autotransplantation do not differ appreciably from control levels, regardless of cryopreservation technique.

show abstract

“…The ovarian tissue is able to restart folliculogenesis up to ovulation when grafted either to an orthotopic site (ovarian fossa, remaining ovary) or to a heterotopic site (e.g., peritoneal abdominal wall, uterine serosa, subcutaneously on the abdominal wall or in the forearm). Despite the fact that ovulation, egg retrieval, in vitro fertilization, and early-stage embryo development can occur after heterotopic transplantation and lead to biochemical pregnancy, ongoing pregnancy and delivery have been obtained only after orthotopic graft at the ovarian site [63–66]. After the transplant, variability has been observed in the time needed to restore ovarian activity and in the lifespan of the graft.…”

Section: Transplantation Of Ovarian Tissuementioning

confidence: 99%

Multiple Approaches for Individualized Fertility Protective Therapy in Cancer Patients

Demeestere

Moffa

Peccatori

et al. 2012

Obstetrics and Gynecology International

View full text Add to dashboard Cite

In the last decade, fertility preservation has risen as a major field of interest, creating new interactions between oncologists and gynecologists. Various options, such as cryopreservation of ovarian tissue, have been developed and are currently routinely proposed in many centers. However, many of the options remain experimental and should be offered to patients only after adequate counseling. This paper addresses the efficiency and the potential of the different fertility preservation approaches.

show abstract

Successful human ovarian autotransplantation to the upper arm

Cited by 8 publications

References 7 publications

A Study Protocol for the Australasian Oncofertility Registry: Monitoring Referral Patterns and the Uptake, Quality, and Complications of Fertility Preservation Strategies in Australia and New Zealand

A Study Protocol for the Australasian Oncofertility Registry: Monitoring Referral Patterns and the Uptake, Quality, and Complications of Fertility Preservation Strategies in Australia and New Zealand

Expression of angiogenic factors in cryopreserved mouse ovaries after heterotopic autotransplantation

Multiple Approaches for Individualized Fertility Protective Therapy in Cancer Patients

Contact Info

Product

Resources

About